RxDoctor Payments Data

Andrew Kwong

Optometrist · Las Vegas, NVNPI 1306298898

Payments from drug & device makers

$908in general payments, 2019–2025

Across 20 payments — averaging $45.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$206
  • Alcon$196
  • Shire North American Group Inc$125
  • Aerie Pharmaceuticals, Inc.$124
  • AbbVie$109
  • Amgen$91
  • plus $58 from 2 others

What the payments were for

  • Food & beverage$908100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$908 in reported general payments places this provider in the 50th percentile of 494 optometrist providers in Nevada.

See all optometrist providers in Nevada

Medicare billing

Part B allowed, 2024
$237,748
Medicare patients
837
Services billed
2,875

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast31$49,190
LumiganBimatoprost72$48,787
RestasisCyclosporine36$33,627
RocklatanNetarsudil Mesylat/Latanoprost17$13,529
MieboPerfluorohexyloctane/Pf13$9,824
SimbrinzaBrinzolamide/Brimonidine Tart19$5,474
Latanoprost243$3,343
Cyclosporine12$3,325
Prednisolone Acetate20$1,002
Brimonidine Tartrate63$960
Dorzolamide Hcl25$583
Timolol Maleate63$549
Tobramycin-DexamethasoneTobramycin/Dexamethasone11$516
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat42$346
Doxycycline Monohydrate21$210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$109$82,415108 claims
Aerie Pharmaceuticals, Inc.Rocklatan$124$13,52917 claims
AlconSimbrinza$196$5,47419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 494 optometrist providers in Nevada.

Other optometrist in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →